

# Journal of Visualized Experiments

## Examining the Dynamics of Cellular Adhesion and Spreading of Epithelial Cells on Fibronectin During Oxidative Stress

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE59989R3
<b>Full Title:</b>	Examining the Dynamics of Cellular Adhesion and Spreading of Epithelial Cells on Fibronectin During Oxidative Stress
<b>Keywords:</b>	cell adhesion; cellular spreading; Oxidative stress; fibronectin; epithelial cells; ATM inhibition; ruffles; stress fibers; cell circularity
<b>Corresponding Author:</b>	Melissa C. Srougi, Ph.D. High Point University High Point, NC UNITED STATES
<b>Corresponding Author's Institution:</b>	High Point University
<b>Corresponding Author E-Mail:</b>	msrougi@highpoint.edu;msrougi@hotmail.com
<b>Order of Authors:</b>	Caitlin E Tolbert Lindsey Palmquist Hannah Lee Dixon Melissa C. Srougi, Ph.D.
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Raleigh, NC USA

**TITLE:**

Examining the Dynamics of Cellular Adhesion and Spreading of Epithelial Cells on Fibronectin During Oxidative Stress

**AUTHORS AND AFFILIATIONS:**

Caitlin E. Tolbert<sup>1</sup>, Lindsey Palmquist<sup>2</sup>, Hannah Lee Dixon<sup>2</sup>, Melissa C. Srougi<sup>2</sup>

<sup>1</sup>Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>2</sup>Department of Chemistry, High Point University, High Point, NC

Email addresses of co-authors:

Caitlin E. Tolbert (Caitlin.Tolbert@crick.ac.uk)

Lindsey Palmquist (lpalmqui@highpoint.edu)

Hannah Lee Dixon (hdixon@highpoint.edu)

Corresponding author, current address and affiliation:

Melissa C. Srougi (mcsrougi@ncsu.edu)

**KEYWORDS:**

cell adhesion, cellular spreading, oxidative stress, fibronectin, epithelial cells, ATM inhibition, ruffles, stress fibers, cell circularity

**SUMMARY:**

This method is useful for quantifying the early dynamics of cellular adhesion and spreading of anchorage-dependent cells onto the fibronectin. Furthermore, this assay can be used to investigate the effects of altered redox homeostasis on cell spreading and/or cell adhesion-related intracellular signaling pathways.

**ABSTRACT:**

The adhesion and spreading of cells onto the extracellular matrix (ECM) are essential cellular processes during organismal development and for the homeostasis of adult tissues. Interestingly, oxidative stress can alter these processes, thus contributing to the pathophysiology of diseases such as metastatic cancer. Therefore, understanding the mechanism(s) of how cells attach and spread on the ECM during perturbations in redox status can provide insight into normal and disease states. Described below is a step-wise protocol that utilizes an immunofluorescence-based assay to specifically quantify cell adhesion and spreading of immortalized epithelial cells on fibronectin (FN) in vitro. Briefly, anchorage-dependent cells are held in suspension and exposed to the ATM kinase inhibitor Ku55933 to induce oxidative stress. Cells are then plated on FN-coated surface and allowed to attach for predetermined periods of time. Cells that remain attached are fixed and labeled with fluorescence-based antibody markers of adhesion (e.g., paxillin) and spreading (e.g., F-actin). Data acquisition and analysis are performed using commonly available laboratory equipment, including an epifluorescence microscope and freely available Fiji software. This procedure is highly versatile and can be modified for a variety of cell

lines, ECM proteins, or inhibitors in order to examine a broad range of biological questions.

## **INTRODUCTION:**

Cell-matrix adhesions (i.e., focal adhesions) are large and dynamic multimolecular protein complexes which mediate cell adhesion and spreading. These processes are critical for tissue development, maintenance, and physiological function. Focal adhesions are composed of membrane-bound receptors, such as integrins, as well as scaffolding proteins that link cytoskeletal actin to the extracellular matrix (ECM)<sup>1</sup>. These complexes are capable of responding to physiochemical cues present in the extracellular environment through the activation of various signaling transduction pathways. As such, focal adhesions serve as signaling centers to propagate extracellular mechanical cues into a number of cellular processes including directed migration, cell cycle regulation, differentiation, and survival<sup>1,2</sup>. One group of signaling molecules that regulate and interact with focal adhesions includes members of the Rho family of small GTPases. Rho GTPases are key proteins that regulate cell migration and adhesion dynamics through their specific spatiotemporal activation<sup>3</sup>. Not surprisingly, dysregulation of Rho protein function has been implicated in a number of human pathologies such as metastasis, angiogenesis, and others. Of particular interest, cellular redox status plays a predominant role in the modulation of cell migration and adhesion. Alterations in redox homeostasis, such as increases in reactive oxygen species (ROS), have been demonstrated to regulate Rho protein activity, as well as adhesion, in a number of cell types and human diseases<sup>4-8</sup>. For example, individuals suffering from the neurological disorder ataxia-telangiectasia (A-T), which is caused by a mutation in the DNA damage repair serine/threonine kinase A-T-mutated (ATM), have an increased risk of metastatic cancer<sup>9,10</sup>. Loss of ATM kinase activity in these patients and cell lines, either through genetic mutation or chemical inhibition, results in high levels of oxidative stress due to dysfunction of the pentose phosphate pathway<sup>7,11,12</sup>. Moreover, recent studies from the laboratory have highlighted a pathophysiological role for ROS in A-T by altering cytoskeletal dynamics (i.e. adhesion and spreading) as a direct result of activating Rho family GTPases in vitro<sup>5</sup>. Ultimately, these alterations in cytoskeletal dynamics caused by Rho family activation may lead to the increased risk of metastatic cancer noted in A-T patients<sup>5,13</sup>. Therefore, understanding the interplay between cell-matrix interactions during oxidative stress can provide insights into the regulation of adhesion and spreading. These studies can also set the stage for further investigations into a possible role for Rho family GTPases in these signaling processes.

Described herein is a protocol to study the early cellular dynamics of adhesion assembly and spreading during oxidative stress caused by inhibition of ATM kinase activity. This assay is based on the well-characterized mechanism of anchorage-dependent cells adhesion to the ECM protein fibronectin (FN). When cells maintained in suspension are plated onto FN, several Rho GTPases coordinate the control of the actin cytoskeletal remodeling<sup>3,14</sup>. Morphological changes are observed as cells shift from round and circular in appearance to flattened and expanded. Concomitant with these observations is the development of numerous matrix adhesions with the ECM. These changes are attributed to the biphasic activation of RhoA with Rac1 during the first hour as cells adhere and spread<sup>15,16</sup>.

A variety of methods have been utilized to examine adhesion morphology and dynamics as well

as cell spreading. However, these methods rely on sophisticated long-term, live-imaging total internal reflection fluorescence (TIRF) or confocal microscopy systems. Thus, users must have access to specialized equipment and software. Furthermore, the set-up time required by these bio-imaging systems makes capturing early adhesion events challenging, especially when testing multiple inhibitors or treatment conditions concurrently.

The methods detailed, herein, provide a straightforward, economical, yet quantitative way to assess parameters that govern the adhesion assembly and spreading *in vitro*. The protocol is performed using commonly available laboratory equipment, such as an epifluorescence microscope and CCD camera. This assay involves applying anchorage-dependent cells to an FN-coated surface after a period of oxidative stress caused by chemical inhibition of ATM kinase activity, which has been demonstrated previously<sup>5</sup>. Following plating, cells are allowed to attach and adhere for specified lengths of time. Unattached cells are washed away, while attached cells are fixed and labeled with fluorescence-based antibodies to markers of adhesion (e.g., paxillin) and spreading (e.g., F-actin)<sup>2,5</sup>. These proteins are then visualized and recorded using an epifluorescence microscope. Subsequent data analysis is performed using freely available Fiji software. Moreover, this method can be adapted to examine adhesion dynamics under a wide range of conditions including different ECM proteins, treatment with various oxidants/cell culture conditions or a variety of anchorage-dependent cell lines to address a broad range of biological questions.

## **PROTOCOL:**

### **1. Preparations**

NOTE: The protocol described below has been optimized for the use with REF52 cells and ATM<sup>+/+</sup> or ATM<sup>-/-</sup> human fibroblasts. Other cell types may require further optimization as described in the notes and troubleshooting sections below.

1.1. Make 500 mL of complete cell culture medium for REF52 cells. To 500 mL of high-glucose containing Dulbecco's modified Eagle's medium (DMEM) add 10% FBS, 2 mM L-glutamine, and 100 units/mL penicillin-streptomycin.

1.2. Prepare a 25 µg/mL solution of fibronectin (FN) by adding 300 µL of 1 mg/mL FN solution to 12 mL of sterile 1x phosphate buffered saline (PBS), pH 7.4. Mix well.

1.3. Prepare a 0.5% (w/v) delipidated (i.e., fatty acid free) bovine serum albumin (dBSA) solution in serum free DMEM cell culture medium. Add 0.5 g of dBSA to 100 mL of serum free DMEM medium. Mix the solution well, but do not vortex. Sterile filter the solution into a new sterile container, using a 0.22 µm syringe filter before use. Store at 4 °C.

1.4. Make 3.7% paraformaldehyde solution by dissolving 3.7 g of paraformaldehyde in 100 mL of 1x PBS. Use gentle heat and stirring to get the paraformaldehyde into solution.



NOTE: The paraformaldehyde solution is light sensitive and should be protected from light. It is good for up to one week when stored at 4 °C.

CAUTION: Paraformaldehyde is toxic, flammable, corrosive and a health hazard. Review the material safety data sheet for paraformaldehyde prior to use. Use the appropriate personal protective equipment when handling including eye shield, face shield, full-face particle respirator, gloves, and lab coat.

1.5. Prepare the permeabilization solution containing 0.2% non-ionic surfactant in 1x PBS (v/v). For 100 mL, slowly add 0.2 mL of Triton X-100 to 100 mL of 1x PBS, while stirring.

1.6. Make the immunofluorescence blocking buffer containing 2.5% BSA, 5% goat serum, and 0.05% non-ionic surfactant (w/v/v) dissolved in 1x PBS solution. For 100 mL, add 5 mL of goat serum, 2.5 g of BSA and 0.05 mL of Triton X-100 in ~ 95 mL 1x PBS, while stirring.

1.7. Grow REF52 cells in DMEM complete culture medium in a 10 cm<sup>2</sup> (or any other vessel size) cell culture-treated plate in a cell culture incubator at 37 °C and 5% CO<sub>2</sub>.

## **2. Coating cell culture plates with the extracellular matrix protein fibronectin**

NOTE: Perform this section using aseptic technique and sterile reagents in a BSL-2 certified laminar flow hood. Refer to **Figure 1A** for an overview of key steps prior to beginning.

2.1. Using a tissue culture certified 24-well plate, place one glass coverslip (12-Cir-1) in each well. Label the plate according to **Figure 1B**.

2.2. Pipette 500 µL of the 25 µg/mL FN solution to each well of a 24-well plate.

2.3. Pipette the solution over each coverslip a few times to ensure even coating and complete submersion. Place the lid back on the plate.

2.4. Incubate the plate in a cell culture incubator at 37 °C and 5% CO<sub>2</sub> for 1 h.

NOTE: Alternatively, incubate overnight at 4 °C.

2.5. After 1 h, remove the plate from the incubator and aspirate the FN solution from the wells.

2.6. Wash wells three times with 500 µL of 1x PBS. Aspirate the final wash of 1x PBS.

2.7. Block wells with 500 µL of dBSA solution for a minimum of 15 min at 37 °C and 5% CO<sub>2</sub>.

2.8. Aspirate the dBSA solution prior to plating cells in step 3 below.

NOTE: If storing plates, add 500 µL of 1x PBS to each coverslip after aspiration of the dBSA

177 solution. Plates can then be kept at 4 °C for up to one week.

### 179 3. Preparing anchorage-dependent cells for the adhesion assay

181 NOTE: Perform this section using aseptic technique and sterile reagents in a BSL-2 certified  
182 laminar flow hood.

184 3.1. At least 30 min prior to the cell plating, pre-warm the following solutions: DMEM complete  
185 medium, dIBSA solution, 1x PBS, 0.5% trypsin-EDTA solution, and trypsin neutralizing serum (TNS)  
186 in a 37°C water bath.

188 3.2. Starting with a confluent monolayer of REF52 cells in a 10 cm<sup>2</sup> dish, wash cells twice with 6  
189 mL of warm 1x PBS. Serum starve the cells for at least 1 h (depending on cell type) in 6 mL of  
190 warm dIBSA solution.

192 3.3. Wash cells with 6 mL of warmed 1x PBS, aspirate PBS and add 1.5 mL of warm 0.5% Trypsin-  
193 EDTA solution.

195 3.4. Place cells in a cell culture incubator at 37 °C and 5% CO<sub>2</sub> for ~2 min.

197 3.5. Observe cells under a light microscope to ensure the detachment is complete. If cells are still  
198 adherent after tapping the plate on the bench top, return to the 37 °C incubator for an additional  
199 2 min. Trypsinize the cells for as little time as is necessary.

201 3.6. Gently detach cells from the dish using 1.5 mL of warm trypsin neutralizing serum (TNS).  
202 Pipette the solution up and down over the bottom of the plate numerous times to remove all  
203 remaining adherent cells. If cells appear clumpy, further triturate the cell suspension by gently  
204 pipetting up and down over the back of the dish.

206 3.7. Count cells using trypan blue exclusion and a hemocytometer under a light microscope.  
207 Alternatively, use an automated cell counter.

209 3.8. Remove an appropriate amount of cells to create a 1.0 - 3.0 x 10<sup>4</sup> cells/mL cell suspension in  
210 5 mL of dIBSA in a 15 mL conical tube.

212 3.9. Centrifuge cells at ~ 300 x g for 5 min using a fixed angle rotor in a table-top centrifuge.

214 3.10. Aspirate the supernatant from the cell pellet, and resuspend cells in a total of 7 mL of warm  
215 dIBSA solution. Do not allow the cells to be overly confluent upon coverslip plating, but evenly  
216 distributed with few cells touching one another.

218 3.11. Evenly divide the cell suspension into two 15 mL conical tubes, one for the vehicle alone  
219 control (DMSO) and one for Ku55933 (ATM kinase inhibitor, oxidant)<sup>5</sup>. Ensure each tube contains  
220 3.5 mL of the cell suspension.

221  
222 3.12. Using a tube rotator, revolve the tubes at 37 °C for 90-120 min in a cell culture incubator.

223  
224 3.13. 30 min before plating, add a final concentration of 10  $\mu$ M Ku55933 and DMSO (1:1,000) to  
225 each respective tube. Place the cell suspension back on the rotator for the remaining time.

226  
227 3.14. After revolving the cell suspension for 90-120 min, remove 500  $\mu$ L of cell suspension from  
228 each treatment group and add to one FN coated coverslip in the 24-well plate from step 2 as  
229 illustrated (**Figure 1B**). Return the plate to the 37 °C and 5% CO<sub>2</sub> cell culture incubator and the  
230 cell suspension back to the rotation.

231  
232 3.15. After plating the cell suspension on the FN covered-coverslips, allow cells to adhere for the  
233 desired length of time (e.g., 10 min, 15 min, 20 min, 30 min) and then immediately proceed to  
234 step 4.

#### 235 236 **4. Cell fixation and antibody staining for immunofluorescence**

237  
238 NOTE: The following steps are performed under non-sterile conditions and at room temperature  
239 unless otherwise stated.

240  
241 4.1. After the desired time for adhesion has passed, aspirate the cell solution from each coverslip  
242 in the plate.

243  
244 4.2. Using the sides of the well, gently dispense 500  $\mu$ L of 3.7% paraformaldehyde solution onto  
245 each coverslip and wait 10-15 min.

246  
247 4.3. Remove the paraformaldehyde solution and wash each coverslip with 500  $\mu$ L of 1x PBS for a  
248 total of two times.

249  
250 NOTE: Dispose of paraformaldehyde waste responsibly, according to the institution's  
251 environmental health and safety plan.

252  
253 4.4. Aspirate the PBS, and permeabilize cells on each coverslip with 500  $\mu$ L of 0.2% Triton X-100  
254 in 1x PBS (v/v) for 10-15 min at room temperature.

255  
256 4.5. Wash each coverslip with 500  $\mu$ L of 1x PBS three times.

257  
258 4.6. Block cells on each coverslip with 500  $\mu$ L of immunofluorescence blocking buffer containing  
259 5% goat serum, 2.5% BSA and 0.05% Triton X-100 dissolved in a 1 x PBS solution for 30-60  
260 minutes.

261  
262 4.7. Dilute the primary anti-paxillin antibody (1:250) in the blocking buffer. Mix well and add 200  
263  $\mu$ L of the antibody solution to each coverslip. Incubate at room temperature for at least 1 h.

NOTE: Alternatively, the primary antibody solution can be incubated overnight at 4 °C. There are many common focal adhesion markers that could be used for staining adhesion complexes and subsequent FA analysis. These include antibodies against the following proteins: integrin subunits ( $\beta 1$ ,  $\alpha 5$ , or  $\alpha V$ ), talin, or vinculin<sup>2</sup>.

4.8. Aspirate the antibody solution, and wash each coverslip with 500  $\mu$ L of 1x PBS three times for 10 min each. Protect the samples from light from this point forward.

4.9. Dilute the phalloidin F-actin probe conjugated to the red fluorescent Alexa 594 dye (1:1000) and goat-anti mouse 488 fluorescent secondary antibody (1:400) in the same blocking buffer solution. Mix well and add 200  $\mu$ L of the antibody solution to each coverslip for 30 min.

NOTE: Fluorescently conjugated secondary antibodies from other species may be used as well. However, the use of antibodies from other species will require modification of the blocking buffer serum.

4.10. Aspirate the antibody solution, and wash each coverslip with 500  $\mu$ L of 1x PBS three times for 10 min each.

4.11. Aspirate the 1x PBS and rinse one time with 500  $\mu$ L of dH<sub>2</sub>O.

4.12. Fix coverslips onto microscope slides using anti-fade mounting medium containing DAPI.

4.13. Leave microscope slides to set overnight in the dark at room temperature.

4.14. Store microscope slides in the dark at 4 °C for the long-term storage and until imaging.

NOTE: Image using standard immunofluorescence techniques. It is recommended to use a high-powered oil immersion 60x objective lens to ensure enough resolution to note the focal adhesions and peripheral ruffles at cell edges. Acquire images of 20-30 cells in multiple fields of view for each coverslip under each treatment condition and time. From combined replicates, this should yield at least 60 cells in order to perform statistical analysis. Save and export fluorescence images as a .TIFF file with a minimum of 300 dpi resolution.

## 5. Quantifying stress fibers, cell circularity, and focal adhesion formation

NOTE: The following image analyses are performed using the latest version of the open source imaging processing package Fiji Is Just Image J (Fiji), which can be downloaded free of charge at (<http://fiji.sc/>).

### 5.1. General image processing

NOTE: All images will need to be prepared for computational analyses by performing steps 5.1.1-

5.1.5 below (**Figure 2**). Afterward, any or all subsequent quantification procedures may be selected.

5.1.1. Open the .TIFF fluorescence image using Fiji. Ensure the images are 8-bit and grayscale.

5.1.2. Select **Image-Adjust-Window/level** and select **Auto (Figure 2A)**.

5.1.3. Select **Process-Subtract Background** to subtract the background fluorescence. Check **Sliding Paraboloid** and select the option of a **Rolling Ball Radius** of 50 pixels (**Figure 2B**).

NOTE: To verify the proper size for the rolling ball radius, select the **Line Tool** and draw a radius on the largest adhesion in the image. Select **Measure** to verify the length of the line drawn. If the value of the radius is too large, features including adhesions will be lost in the image. If the radius is too small, it will give rise to artifacts in the processed image due to background noise.

5.1.4. Select **Image-Adjust- Brightness/Contrast** to check the intensity of the adhesion over the background. Adjust if necessary.

NOTE: To optimize the brightness/contrast and avoid saturating the signal, use the lookup tool of the image to examine its histogram to adjust the brightness/contrast.

5.1.5. Select the following parameters under **Analyze-Set Measurements**: Area, Mean Gray Value, Shape Descriptors, and Integrated Density.

## **5.2 Stress fiber formation analysis**

NOTE: Stress fibers can be quantified multiple ways depending on the phenotype.

5.2.1. Count the number of cells with stress fibers as a percentage over the total number of cells. This analysis is best if there are visual differences in the number of stress fibers formed under different experimental conditions.

5.2.2. Count the number of stress fibers that transverse the cell. This analysis allows for the comparison of the number of stress fibers formed per cell.

5.2.3. Measure the total fluorescence intensity given by the phalloidin (e.g., F-actin) staining per cell<sup>17,18</sup>. This method will highlight drastic increases/decreases in fluorescence intensity due to F-actin staining.

5.2.3.1. Set the measurement parameters in step 5.1.5 above.

5.2.3.2. Select the **Freehand Tool** in the Fiji toolbar and manually trace the cell(s) of interest. Select **Analyze-Measure**. A new window will appear showing the selected measurement parameters.

5.2.3.3. Select the **Freehand Tool** in the Fiji toolbar and manually trace an empty space with no cells present. Select **Analyze-Measure**. This measurement will serve as the background fluorescence.

5.2.3.4. Use the equation below to determine the total F-actin fluorescence per cell:

$$F - \text{actin Fluorescence Per Cell} = (\text{Integrated Density of Measured Cell}) - (\text{Area of Measured Cell} \times \text{Mean Fluorescence of the Background})$$

NOTE: The resulting measurement can be normalized and compared to other cells to give F-actin fluorescence per cell.

### 5.3. Cell circularity analysis

NOTE: Information on cell area (an indicator of cell spreading over time), as well as, the circularity can also be recorded. This measurement is given as a ratio between 0 to 1 as a way to quantify cells that are elongated to round, respectively.

5.3.1. Select the **Freehand Tool** in the Fiji toolbar, and trace an individual cell. Select **Image-Measure** and record the cell area and perimeter measurements for each cell. Repeat this procedure for each cell.

NOTE: Under the **Set Measurements** function, circularity is provided as the **Shape Descriptors** measurement (step 5.1.5).

5.3.2. Manually count actin-enriched ruffling or protrusions per cell as depicted in **Figures 3 and 4**.

### 5.4. Focal adhesion analysis

NOTE: Before performing focal adhesion analysis, install the Mexican Hat Filter plugin on the latest version of Fiji. The following protocol has been modified from previous studies<sup>19-21</sup>.

5.4.1. Select **Process-Enhance Local Contrast (Clahe)** using a block size of 19, histogram bins 256, and a maximum slope of 6, with no mask and not fast. (**Figure 2C**)

5.4.2. Select **Process-Filters- Gaussian Blur** with a Sigma (Radius) of 2.0 to filter the image (**Figure 2D**).

5.4.3. Select **Plugins-Mexican Hat Filter (Mhf)** with a Radius of 2.0 (**Figure 2E**).

5.4.4. Run **Threshold** and select **Dark Background** and **Over/Under** using either **Huang** or **Isodata** as the thresholding method. Select **Auto-Threshold**.

NOTE: This step ensures that adhesions are highlighted, but also distinct from one another.

5.4.5. Select **Analyze-Analyze Particles** with the following parameters selected: size=20, pixels-infinity and circularity=0.00-0.99. Check the outlines to ensure the proper detection and separation of focal adhesions.

NOTE: These results yield the number, area, and shape description of individual focal adhesions.

## REPRESENTATIVE RESULTS:

### A general schema of the experimental set-up

**Figure 1** represents the general schema for the cell adhesion and spreading protocol beginning with serum starvation of REF52 cells and ending with computational analysis of acquired fluorescence images. Key steps in the protocol are illustrated in the timeline. Of note, step 2 of the protocol describes the preparation of the FN-coated coverslips, which should be performed concurrently with step 3: serum starving REF52 cells prior to placing them in suspension (**Figure 1A**). An example of a mock-labeled 24-well plate indicating treatment groups and duration of cell adhesion prior to fixation of samples for fluorescence microscopy (**Figure 1B**).

### Immunofluorescence image processing for focal adhesion quantification

REF52 cells were held in suspension for 90 minutes, plated on FN, and allowed to adhere for an additional 15 minutes. After fixation and staining with an anti-paxillin antibody, fluorescent 8-bit grayscale images of the cells were acquired. Image processing analysis was performed according to the protocol delineated in Step 5. Shown are representative images of each distinct processing step including the original image (**Figure 2A**), and images following background subtraction (post-Rolling Ball) (**Figure 2B**), CLAHE (**Figure 2C**), Gaussian Blur (**Figure 2D**) and Mexican Hat Filter (Post-MHF) (**Figure 2E**) filtering steps. After completing all image processing steps, individual focal adhesions should be prominent, in focus, and readily distinguishable from one another (**Figure 2E**). After the images are filtered, the focal adhesions can be quantified and their area measured (steps 5.1 and 5.4).

### Visualization of cell adhesion and spreading on FN after oxidative stress

A representative grayscale fluorescence image of anti-paxillin (focal adhesion marker) (**Figure 3**, top panel) and phalloidin F-actin probe staining (**Figure 3**, bottom panel) of REF52 cells after plating on FN with or without Ku55933 (ROS-inducing agent) treatment. Prior to the assay, REF52 cells were serum starved for 1 h. Following serum starvation, cells were held in suspension while being treated with either vehicle alone or 10  $\mu$ M Ku55933 to induce oxidative stress. Cells were plated on FN-coated coverslips for the indicated times, fixed, and then stained with an antibody to focal adhesions and phalloidin to detect F-actin proteins. Prominent focal adhesions and stress fibers should be readily visible in REF52 cells after being allowed to adhere for 20-30 min on FN. Plated cells should not overlap with one another to permit full cellular spreading after adhesion. Notice the clear, distinct cell edges as well as space for individual cells to spread (**Figure 3**). F-actin enriched ruffles at the leading edge of cell membranes are visible and indicated with an

arrow (**Figure 3**, bottom panel).

### **Graphical representation of quantified fluorescence images of stress fibers and the degree of cell spreading**

Examples of quantified images displayed in bar graph form representing the percentage of cells with stress fibers and the degree of cell spreading with and without Ku55933 treatment at various times after adhesion. Fluorescent images of phalloidin F-actin probe and anti-paxillin staining, similar to images shown in **Figure 3**, were analyzed for the percentage of stress fibers and cell spreading (i.e., circularity index) using the image analysis procedures described in step 5 of the protocol. Notably, oxidant treatment caused a significant increase in stress fiber formation at all adhesion time points examined (**Figure 4A**) and a decrease in cell spreading following 15 minutes of cell adhesion to FN (**Figure 4B**).

### **Non-quantifiable immunofluorescence images due to cellular over confluency**

Serum-starved REF52 cells were held in suspension for 90 minutes, during which time they were treated with 10  $\mu$ M Ku55933 to induce ROS formation. Cells were then plated on FN and allowed to adhere for 20 minutes, after which they were fixed and stained with anti-paxillin or phalloidin-Alexa 594 F-actin probe. Plating at higher cell densities leads to cellular crowding, which prohibits cells from fully spreading due to over confluency. Notice cell edges are indistinguishable from adjacent cells (yellow arrows) (**Figure 5A**). As a result, quantification of individual cells is precluded, and spreading circumference cannot be accurately determined. In **Figure 5B**, a separate cell line, mouse embryonic fibroblasts (MEF), were held in suspension and then plated on FN for 30 minutes. Cells were then fixed and stained with an anti-paxillin antibody. Out of focus cells are denoted by red arrows (**Figure 5B**). Furthermore, the cross-reactivity of the anti-paxillin antibody with cellular debris (blue arrow) will alter thresholding during quantitative image analysis (Part 5) and should not be included in the analysis (**Figure 5B**).

### **FIGURE LEGENDS:**

**Figure 1: Time-line of protocol and example 24-well plate set-up.** (A) The time-line highlights key steps in the cell adhesion and spreading procedure. (B) Representative labeled 24-plate, illustrating treatment groups and times for cell adhesion.

**Figure 2: Examples of representative immunofluorescence images following image-processing.** REF52 cells were held in suspension for 90 min, plated on FN, and allowed to adhere for 15 min. Cells were fixed and stained with an anti-paxillin antibody. (A) Original image and images following (B) Background subtraction (post-Rolling Ball), (C) CLAHE, (D) Gaussian Blur and (E) Mexican Hat Filter (Post-MHF) filtering steps. Bar, 20  $\mu$ m.

**Figure 3: Representative immunofluorescence images of anti-paxillin and phalloidin F-actin probe stained REF52 cells plated on FN.** Prior to the assay, REF52 cells were serum starved for 1 h. Following serum starvation, cells were held in suspension while treated with either vehicle alone or 10  $\mu$ M Ku55933 to cause oxidative stress. Cells were plated on FN-coated coverslips for the indicated times, fixed and stained with an antibody to focal adhesions and phalloidin to detect F-actin proteins. F-actin enriched ruffles at the leading edge of cell membranes are



indicated with an arrow. Bar, 40  $\mu$ m. This figure has been modified from Tolbert et al.<sup>5</sup>

**Figure 4: Quantification of immunofluorescence images.** Graphs illustrating (A) the percentage of cells exhibiting stress fibers and (B) cell circularity measurements. Cell circularity was defined as the cell area divided by the cell perimeter. Values ranged from 0-1.0 indicating an elongated or rounded morphology, respectively. Error bars indicate S.E.M. Student's *t*-test for paired samples \* $p \leq 0.01$  from experiments performed in triplicate. This figure has been modified from Tolbert et al.<sup>5</sup>

**Figure 5: Non-quantifiable immunofluorescence images.** (A) Serum-starved REF52 cells were held in suspension for 90 min, while treated with 10  $\mu$ M Ku55933. Cells were plated on FN and allowed to adhere for 20 min. Cells were fixed and stained with anti-paxillin or phalloidin-Alexa 594 F-actin probe. Cell edges are shown by yellow arrows. (B) MEF cells were held in suspension and then plated on FN for 30 min. Cells were fixed and stained with an anti-paxillin antibody. Out of focus cells are denoted by red arrows and cross-reactivity of anti-paxillin antibody with cellular debris are denoted with blue arrows. Bar, 30  $\mu$ m.

## DISCUSSION:

The protocol described here is a versatile and economical way to rapidly screen a number of anchorage-dependent cell types for dynamic cytoskeleton remodeling during cell spreading. In particular, this method quantitatively examines stress fiber and focal adhesion formation during oxidative stress when cells adhere to FN (**Figure 1A**). Moreover, these cellular phenotypes may suggest a regulatory role for members of the Rho family of small GTPases since they have documented roles during cell attachment and spreading<sup>15,16,22</sup>. However, additional biochemical techniques would be required to identify the possible involvement of GTP-bound, active Rho family proteins.

The presented protocol utilizes immunofluorescence detection of F-actin and paxillin to specifically examine cell adhesion and spreading of immortalized epithelial cells on FN after oxidative stress induced by ATM kinase inhibition (**Figures 2-4**). However, this procedure can also be adapted for use on other ECM proteins and/or for other adherent cell types. When adapting to other cell lines, it is important to optimize the experimental conditions, particularly: cell number/density, time of serum starvation, ECM protein concentration, and oxidative stress treatment conditions. When testing the effects of an unknown stimulus on adhesion and spreading dynamics, it is necessary to include both negative and positive control samples to verify that the assay is functioning correctly. Negative control samples can include an untreated or vehicle-only sample, while a positive control should induce oxidative stress (e.g.,  $H_2O_2$ ). Furthermore, although not discussed here, it is also essential to utilize the proper antibody controls. It is recommended that three separate controls be used for each antibody to verify its specificity and to identify any potential fluorescence bleed-through<sup>23,24</sup>. These include: 1) a primary antibody control to ensure specific binding of the primary antibody to the antigen and to confirm that antigen binding occurs under the fixation conditions used, 2) a secondary antibody control (for non-secondary conjugated-antibodies) that shows specificity to the primary antibody, and 3) fluorophore controls that ensure the fluorophore added is not the result of

endogenous fluorescence or bleed-through from another antibody.

While this assay is useful for analyzing the early kinetic events of adhesion assembly and spreading, it is not suitable for the detailed examination of adhesion disassembly or adhesion strength and cellular reinforcement. The latter requires the use of long-term imaging bio-stations or single-cell force spectroscopy techniques. The latter techniques include atomic-force microscopy, optical tweezers, tension sensors of adhesion proteins such as vinculin<sup>25</sup> or talin<sup>26,27</sup>, and 3D-force microscopy<sup>28</sup>.

Critical steps in the protocol include thoroughly coating coverslips with FN. This is necessary for the uniform spreading and adhesion of cells. It is therefore important to pipette the FN solution up and down over the coverslips multiple times prior to incubation. Coverslips must remain fully submerged in the FN solution during the incubation time. FN coated coverslips can be stored for up to 2 weeks at 4°C.

Cell density is also important, as cells that are plated too densely will not achieve maximum spreading circumference. Furthermore, it would not be possible to distinguish individual focal adhesions or cellular ruffles for each individual cell. It is, therefore, necessary to count the cells using a hemocytometer or automated cell counter prior to placing the cells in suspension. While an estimate of cell density is provided for REF52 cells, this will need to be empirically determined for other cells under study. Cells should be plated sparsely enough that few cells overlap, allowing them to spread fully (**Figure 5**).

Other critical steps in the protocol to consider are fluorescently conjugated phalloidin-Alexa 594 F-actin probe and secondary antibodies are light sensitive. Therefore, samples should be minimally exposed to light after the application of these reagents. Furthermore, a number of agents that induce oxidative stress have short half-lives. It is, therefore, necessary to test the chosen oxidant for optimal dose and exposure time to achieve peak activity.

The following sections contain trouble-shooting tips with regards to FN concentration, serum starvation conditions, and cell detachment methodologies. These tips are useful when adapting the protocol for other cells lines and/or treatment conditions.

For consistent FA analysis, optimal attachment and spreading conditions are necessary, which will vary depending upon the ECM ligand. For FN, begin using a dynamic range of 10-30 µg/mL. At higher concentrations of FN, there is little difference in cell attachment. However, some cell types do not efficiently spread at higher concentrations of ECM.

Each cell type responds differently to conditions of serum starvation. REF52 cells can easily be starved overnight without any loss of viability, however, this is not true for all cell lines. Therefore, it is necessary to determine the degree to which the cell line under study can withstand serum starvation.

For spreading assays, cells need to be trypsinized for as little time as possible for reproducible

results<sup>29</sup>. Following cell detachment by trypsinization, cell surface receptors, their cognate ligands, and Rho GTPase activity require a recovery period to return to steady-state levels<sup>14,15</sup>. The trypsinization procedure outlined in this protocol should enable cells to retain most of their cell surface FN-binding receptors<sup>29</sup>. However, certain cell types may require alternative methods of cell detachment to completely prevent digestion of cell surface receptors. These methods include chelating cells using EDTA-based solutions (e.g., Versene) or milder enzymatic dissociation solutions (e.g., Accutase). Use of these dissociation solutions may leave cell-cell adhesions intact resulting in cell clumps. It is therefore important to completely resuspend individual cells to ensure experimental reproducibility.

#### ACKNOWLEDGMENTS:

The authors thank Drs. Scott R. Hutton and Meghan S. Blackledge for the critical review of the manuscript.

#### DISCLOSURES:

The authors declare that they have no competing financial interests.

























#### REFERENCES:


- 1 Geiger, B., Bershadsky, A., Pankov, R., Yamada, K. M. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. *Nature Reviews: Molecular Cell Biology*. **2** (11), 793-805, (2001).
- 2 Geiger, B., Yamada, K. M. Molecular architecture and function of matrix adhesions. *Cold Spring Harbor Perspectives in Biology*. **3** (5), pii: a005033 (2011).
- 3 Lawson, C. D., Burridge, K. The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration. *Small GTPases*. **5** e27958 (2014).
- 4 Heo, J., Campbell, S. L. Mechanism of redox-mediated guanine nucleotide exchange on redox-active Rho GTPases. *Journal of Biological Chemistry*. **280** (35), 31003-31010 (2005).
- 5 Tolbert, C. E., Beck, M. V., Kilmer, C. E., Srougi, M. C. Loss of ATM positively regulates Rac1 activity and cellular migration through oxidative stress. *Biochemical and Biophysical Research Communications*. **508** (4), 1155-1161 (2019).
- 6 Hobbs, G. A. et al. Redox regulation of Rac1 by thiol oxidation. *Free Radical Biology and Medicine*. **79** 237-250 (2015).
- 7 Zhang, Y. et al. Mitochondrial redox sensing by the kinase ATM maintains cellular antioxidant capacity. *Science Signaling*. **11** (538), (2018).
- 8 Hobbs, G. A., Zhou, B., Cox, A. D., Campbell, S. L. Rho GTPases, oxidation, and cell redox control. *Small GTPases*. **5** e28579 (2014).
- 9 Shiloh, Y., Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nature Reviews: Molecular Cell Biology*. **14** (4), 197-210 (2013).
- 10 Lang, L. et al. ATM-Mediated Phosphorylation of Cortactin Involved in Actin Polymerization Promotes Breast Cancer Cells Migration and Invasion. *Cellular Physiology and Biochemistry*. **51** (6), 2972-2988 (2018).
- 11 Peter, Y. et al. Elevated Cu/Zn-SOD exacerbates radiation sensitivity and hematopoietic abnormalities of Atm-deficient mice. *European Molecular Biology Organization Journal*. **20** (7), 1538-1546 (2001).

- 12 Takao, N., Li, Y., Yamamoto, K. Protective roles for ATM in cellular response to oxidative stress. *Federation of European Biochemical Societies Letters*. **472** (1), 133-136 (2000).
- 13 Jansen, S., Gosens, R., Wieland, T., Schmidt, M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. *Pharmacology & Therapeutics*. **183** 1-21 (2018).
- 14 Berrier, A. L., Martinez, R., Bokoch, G. M., LaFlamme, S. E. The integrin beta tail is required and sufficient to regulate adhesion signaling to Rac1. *Journal of Cell Science*. **115** (Pt 22), 4285-4291 (2002).
- 15 Arthur, W. T., Petch, L. A., Burridge, K. Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism. *Current Biology*. **10** (12), 719-722 (2000).
- 16 Arthur, W. T., Burridge, K. RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. *Molecular Biology of the Cell*. **12** (9), 2711-2720 (2001).
- 17 Chandra, S., Kalaivani, R., Kumar, M., Srinivasan, N., Sarkar, D. P. Sendai virus recruits cellular villin to remodel actin cytoskeleton during fusion with hepatocytes. *Molecular Biology of the Cell*. **28** (26), 3801-3814 (2017).
- 18 Fitzpatrick, M. *Measuring Cell Fluorescence Using ImageJ*, <<https://theolb.readthedocs.io/en/latest/imaging/measuring-cell-fluorescence-using-imagej.html>> (2014).
- 19 Berginski, M. E., Vitriol, E. A., Hahn, K. M., Gomez, S. M. High-resolution quantification of focal adhesion spatiotemporal dynamics in living cells. *PLoS One*. **6** (7), e22025 (2011).
- 20 Horzum, U., Ozdil, B., Pesen-Okvur, D. Step-by-step quantitative analysis of focal adhesions. *MethodsX*. **1**, 56-59 (2014).
- 21 Elosgui-Artola, A. et al. Image analysis for the quantitative comparison of stress fibers and focal adhesions. *PLoS One*. **9** (9), e107393 (2014).
- 22 Meller, J., Vidali, L., Schwartz, M. A. Endogenous RhoG is dispensable for integrin-mediated cell spreading but contributes to Rac-independent migration. *Journal of Cell Science*. **121** (Pt 12), 1981-1989 (2008).
- 23 Donaldson, J. G. Immunofluorescence Staining. *Current Protocols in Cell Biology*. **69** (4 3), 1-7 (2015).
- 24 Burry, R. W. Controls for immunocytochemistry: an update. *Journal of Histochemistry and Cytochemistry*. **59** (1), 6-12 (2011).
- 25 Grashoff, C. et al. Measuring mechanical tension across vinculin reveals regulation of focal adhesion dynamics. *Nature*. **466** (7303), 263-266 (2010).
- 26 Kumar, A. et al. Correction: Talin tension sensor reveals novel features of focal adhesion force transmission and mechanosensitivity. *Journal of Cell Biology*. **214** (2), 231 (2016).
- 27 Kumar, A. et al. Talin tension sensor reveals novel features of focal adhesion force transmission and mechanosensitivity. *Journal of Cell Biology*. **213** (3), 371-383 (2016).
- 28 Friedrichs, J., Helenius, J., Muller, D. J. Quantifying cellular adhesion to extracellular matrix components by single-cell force spectroscopy. *Nature Protocols*. **5** (7), 1353-1361 (2010).
- 29 Brown, M. A. et al. The use of mild trypsinization conditions in the detachment of endothelial cells to promote subsequent endothelialization on synthetic surfaces. *Biomaterials*. **28** (27), 3928-3935 (2007).

**A.**



	Treatment					
	DMSO			Ku55933		
Time (min)						
10						
15						
20						
30						








Figure 4







Name of Material/ Equipment	Company	Catalog Number
0.05% Trypsin-EDTA (1x)	Gibco by Life Technologies	25300-054
10 cm <sup>2</sup> dishes	Cell Treat	229620
15 mL conical tubes	Fisher Scientific	05-539-5
1X Phosphate Buffered Saline	Corning Cellgro	21-031-CV
24-well cell culture treated plates	Fisher Scientific	07-200-740
4°C refrigerator	Fisher Scientific	
Mouse IgG anti-paxillin primary antibody (clone 165)	BD Transduction Laboratories	610620
Aspirator	Argos	EV310
Biosafety cabinet	Nuair	NU-477-400
Delipidated Bovine Serum Albumin (Fatty Acid Free) Powder	Fisher Scientific	BP9704-100
Dimethyl Sulfoxide	Fisher Scientific	BP231-100
Dulbecco's Modified Eagle Media, High Glucose	Fisher Scientific	11965092
Fetal bovine serum	Fisher Scientific	<a href="#">16000044</a>
Fiji	National Institutes of Health	<a href="http://fiji.sc/">http://fiji.sc/</a>
Filter syringe	Fisher Scientific	6900-2502
Glass coverslips (12-Cir-1.5)	Fisher Scientific	12-545-81
Goat anti-mouse IgG secondary antibody Alexa Fluor 488	Invitrogen	A11001
Goat Serum	Gibco by Life Technologies	16210-064
Hemocytometer	Fisher Scientific	<a href="#">22-600-107</a>
Human Plasma Fibronectin	Gibco by Life Technologies	33016-015
IX73 Fluorescence Inverted Microscope	Olympus	
Ku55933	Sigma-Aldrich	SML1109-25MG
L-glutamine	Fisher Scientific	<a href="#">25-030-081</a>
Monochrome CMOS 16 bit camera	Optimos	
Paraformaldehyde	Sigma-Aldrich	P6148-500G
Penicillin-streptomycin	Fisher Scientific	<a href="#">15-140-122</a>
Alexa Fluor 594 phalloidin (F-actin probe)	Invitrogen	A12381
ProLong Gold Anti-fade reagent with DAPI	Invitrogen	P36941
REF52 cells		
Stir plate with heat control	Corning Incorporated	PC-420D
Syringe	BD Biosciences	309653
Tissue culture incubator	Nuair	
Triton X-100	Fisher Scientific	BP151-500

Trypan Blue Solution  
Trypsin Neutralizing Solution (1x)  
tube rotator  
water bath

Fisher Scientific	<a href="#">15-250-061</a>
Gibco by Life Technologies	R-002-100
Fisher Scientific	11-676-341
Fisher Scientific	FSGPD02

**Comments/Description**

cell dissociation

sterile, tissue culture treated

sterile

PBS, sterile, free of  $Mg^{2+}$  and  $Ca^{2+}$

sterile, tissue culture treated

marker of focal adhesions

Class II, Type A, series 5

dIBSA

organic solvent to dissolve Ku55933

REF52 base cell culture medium

certified, cell culture medium supplement

image analysis program

0.2  $\mu M$ , sterile

autoclave in foil to sterilize

fluorescent secondary antibody, light sensitive

component of blocking solution for immunofluorescence

for cell counting

FN

microscope to visualize fluorescence, cell morphology, counting and dissociation

ATM kinase inhibitor, inducer of reactive oxygen species

cell culture medium supplement

PFA, fixative for immunofluorescence

P/S, antibiotic solution for culture medium

marker of F-actin, light sensitive

cover slip mounting media including nuclear dye DAPI, light sensitive

Graham, D.M. et. al. Journal of Cell Biology 2018

60 mL syringe

detergent used to permeabilize cell membranes

for cell counting

TNS, neutralizes trypsin instead of fetal bovine serum



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: **Examining the dynamics of cellular adhesion and spreading of epithelial cells on fibronectin during oxidative stress**

Author(s): **Caitlin E. Tolbert, Lindsey Palmquist, Hannah Lee Dixon and Melissa C. Srougi**

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

## ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JOVE**” means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JOVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JOVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JOVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JOVE agreeing to publish the Article, the Author hereby grants to JOVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JOVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole



## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:

Melissa C. Srougi

Department:

Chemistry

Institution:

High Point University

Title:

Assistant Professor of Biochemistry

Signature:

Melissa C. Srougi  
*Melissa C. Srougi*

Date:

3/13/19

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



Article #: JOVE\_59989

The responses to the editorial comments are denoted below in italics.

1. The editor has formatted the manuscript to match the journal's style. Please retain the same.

*It has been retained.*

2. Please address all the specific comments marked in the manuscript.

*The specific comments marked in the manuscript have all been addressed and are denoted as track changes in the original Word document.*

3. Once done please proofread the manuscript carefully for any grammar or spelling issues.

*The manuscript has been proofread.*

4. Please also ensure that the highlight is no more than 2.75 pages including headings and spacings.

*The highlighted text is exactly 2.75 pages in length including headings and spacings.*

5. Please print and sign the attached Author License Agreement (ALA). Please write the title and authors of the manuscript and select the right boxes for item 1 and 2. Once completed, please then scan and upload the signed ALA with the manuscript files to your Editorial Manager account.

*The completed and signed ALA has been uploaded to the Editorial Manager account.*

**ELSEVIER LICENSE  
TERMS AND CONDITIONS**

Feb 02, 2019

---

---

This Agreement between Dr. Melissa Srougi ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4521050206086
License date	Feb 02, 2019
Licensed Content Publisher	Elsevier
Licensed Content Publication	Biochemical and Biophysical Research Communications
Licensed Content Title	Loss of ATM positively regulates Rac1 activity and cellular migration through oxidative stress
Licensed Content Author	Caitlin E. Tolbert,Matthew V. Beck,Claire E. Kilmer,Melissa C. Srougi
Licensed Content Date	Jan 22, 2019
Licensed Content Volume	508
Licensed Content Issue	4
Licensed Content Pages	7
Start Page	1155
End Page	1161
Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Intended publisher of new work	other
Portion	figures/tables/illustrations
Number of figures/tables /illustrations	1
Format	both print and electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	Figure 1A-D.
Title of the article	Examining the Dynamics of Cellular Adhesion and Spreading on Fibronectin During Oxidative Stress.
Publication new article is in	Journal of Visualized Experiments
Publisher of the new article	other
Author of new article	Melissa C Srougi
Expected publication date	Sep 2019

Estimated size of new article 8  
(number of pages)

Requestor Location Dr. Melissa Srougi  
Department of Chemistry  
High Point University  
355-D Couch Hall One Univ Parkway  
High Point, NC 27268  
United States  
Attn: Dr. Melissa Srougi

Publisher Tax ID 98-0397604

Total 0.00 USD

Terms and Conditions

### INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

### GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the

transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

### **LIMITED LICENSE**

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be

included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com> . All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

**17. For journal authors:** the following clauses are applicable in addition to the above:

**Preprints:**

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
  - directly by providing copies to their students or to research collaborators for their personal use
  - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above:

Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

**Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the

article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

**Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>.

Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

**20. Other Conditions:**

v1.9

**Questions?** [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

---

---